X43 Stock Overview

A clinical-stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. More details

X43 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 93% below our estimate of its fair value

Risk Analysis

Makes less than USD$1m in revenue ($0)

Volatile share price over the past 3 months compared to the German market

Currently unprofitable and not forecast to become profitable over the next 3 years

Has less than 1 year of cash runway

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Eupraxia Pharmaceuticals Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Eupraxia Pharmaceuticals
Historical stock prices
Current Share Price	CA$3.20
52 Week High	CA$3.86
52 Week Low	CA$2.49
Beta	1.52
1 Month Change	10.15%
3 Month Change	-4.52%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	2.06%

Recent updates

Shareholder Returns

	X43	DE Biotechs	DE Market
7D	-0.8%	-0.8%	0.5%
1Y	n/a	-13.4%	15.8%

Return vs Industry: Insufficient data to determine how X43 performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how X43 performed against the German Market.

Price Volatility

Is X43's price volatile compared to industry and market?
X43 volatility
X43 Average Weekly Movement	9.3%
Biotechs Industry Average Movement	5.7%
Market Average Movement	6.5%
10% most volatile stocks in DE Market	12.8%
10% least volatile stocks in DE Market	3.1%

Stable Share Price: X43's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine X43's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2011	33	James Helliwell	www.eupraxiapharma.com

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company’s lead product candidates include EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and pain relief for knee osteoarthritis, and a product candidate intended for intra-articular use; PROMENADE, which is in a Phase III clinical trial of knee OA patients to evaluate the safety and efficacy of single and repeat doses of EP-104IAR; EP-104GI, which is in a Phase II clinical trial for the treatment of eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. EP-104 consists of a solid core of fluticasone propionate (FP) coated with an outer layer of polyvinyl alcohol (PVA).

Eupraxia Pharmaceuticals Inc. Fundamentals Summary

How do Eupraxia Pharmaceuticals's earnings and revenue compare to its market cap?
X43 fundamental statistics
Market cap	€120.74m
Earnings (TTM)	-€24.16m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-4.9x

P/E Ratio

Is X43 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
X43 income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$27.27m
Earnings	-US$27.27m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-0.76
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did X43 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/22 06:54
End of Day Share Price	2025/05/22 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Eupraxia Pharmaceuticals Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Tania Armstrong-Whitworth	Canaccord Genuity
Gum-Ming Lowe	Craig-Hallum Capital Group LLC
Gary Nachman	Raymond James & Associates

Eupraxia Pharmaceuticals DB:X43 Stock Report